|
ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs. treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC). |
|
|
Consulting or Advisory Role - Nektar; Novartis; Pfizer; Puma Biotechnology |
Research Funding - Genentech/Roche (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Novartis |
|
|
Consulting or Advisory Role - AstraZeneca; Genentech; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Pfizer; Puma Biotechnology |
Research Funding - Bristol-Myers Squibb; Eisai; Eisai; Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
Honoraria - Eisai; Genentech; Genomic Health; Novartis |
Consulting or Advisory Role - Eisai; Nektar |
Speakers' Bureau - Eisai; Genentech; Genomic Health; Novartis |
Research Funding - Bayer; Novartis |
|
|
Consulting or Advisory Role - Angiochem; Genentech/Roche; Kadmon; Lilly; Merrimack; Nektar; Novartis; Sanofi; to-BBB technologies BV |
Research Funding - Angiochem (Inst); Cascadian Therapeutics (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); Puma Biotechnology (Inst); Sanofi (Inst); Tesaro (Inst); to-BBB technologies BV (Inst) |
Patents, Royalties, Other Intellectual Property - Jones and Bartlell; Up to Date.com |
|
|
Honoraria - Celgene; Novartis; Roche |
Speakers' Bureau - Celgene; Novartis; Roche |
Research Funding - Archer (Inst); GenomeDx (Inst); Newlink Genetics (Inst) |
Travel, Accommodations, Expenses - Novartis; Roche |
|
|
Honoraria - Genomic Health |
Consulting or Advisory Role - Amgen |
Speakers' Bureau - Genomic Health |
Research Funding - Eisai (Inst); Genentech (Inst); GTx (Inst); Immunomedics (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Plexxikon (Inst) |
Travel, Accommodations, Expenses - Mylan; Novartis; OBI Pharma; Pfizer; Puma Biotechnology; Roche/Genentech |
|
|
Honoraria - Daiichi Sankyo; Eisai; Nektar |
|
|
Consulting or Advisory Role - Abbvie; Lilly; Novartis; Pfizer; Roche/Genentech |
Speakers' Bureau - Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - Novartis; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
Leadership - NeoGenomics Laboratories |
Stock and Other Ownership Interests - NeoGenomics Laboratories |
Consulting or Advisory Role - BeiGene; Nektar; Pfizer |
|
|
|
|
Stock and Other Ownership Interests - Nektar |
Consulting or Advisory Role - Bluebird Bio (I); Nektar (I) |
Patents, Royalties, Other Intellectual Property - Nektar |
Travel, Accommodations, Expenses - Bluebird Bio (I); Nektar; Nektar (I) |
|
|
Stock and Other Ownership Interests - MedSIR |
Honoraria - Celgene; Eisai; Novartis; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca; Biothera; Celgene; Cellestia Biotech; Roche |